Patents by Inventor Christopher N. Farthing

Christopher N. Farthing has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8962858
    Abstract: Provided are compounds and methods useful for the preparation of compounds useful as inhibitors of beta-site amyloid precursor protein (APP)-cleaving enzyme.
    Type: Grant
    Filed: June 26, 2014
    Date of Patent: February 24, 2015
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Branko Mitasev, Dae-Shik Kim, Huiming Zhang, Christopher N. Farthing
  • Publication number: 20140309429
    Abstract: Provided are compounds and methods useful for the preparation of compounds useful as inhibitors of beta-site amyloid precursor protein (APP)-cleaving enzyme.
    Type: Application
    Filed: June 26, 2014
    Publication date: October 16, 2014
    Inventors: Branko Mitasev, Dae-Shik Kim, Huiming Zhang, Christopher N. Farthing
  • Patent number: 8802871
    Abstract: Provided are compounds and methods useful for the preparation of compounds useful as inhibitors of beta-site amyloid precursor protein (APP)-cleaving enzyme.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: August 12, 2014
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Branko Mitasev, Dae-Shik Kim, Huiming Zhang, Matthew J. Schnaderbeck, Christopher N. Farthing
  • Publication number: 20120190848
    Abstract: Provided are compounds and methods useful for the preparation of compounds useful as inhibitors of beta-site amyloid precursor protein (APP)-cleaving enzyme.
    Type: Application
    Filed: January 20, 2012
    Publication date: July 26, 2012
    Inventors: Branko Mitasev, Dae-Shik Kim, Huiming Zhang, Matthew J. Schnaderbeck, Christopher N. Farthing, Kazuhiro Yoshizawa
  • Patent number: 7893077
    Abstract: Compounds, compositions and methods are provided that are useful in the treatment or prevention of a condition or disorder mediated by PPAR? or PPAR?. In particular, the compounds of the invention modulate the function of PPAR? or PPAR?. The subject methods are particularly useful in the treatment and/or prevention of diabetes, obesity, hypercholesterolemia, rheumatoid arthritis and atherosclerosis.
    Type: Grant
    Filed: November 12, 2008
    Date of Patent: February 22, 2011
    Assignee: Amgen Inc.
    Inventors: Philippe Bergeron, Christopher N. Farthing, Stuart D. Jones, John W. Liebeschuetz, Sarah E. Lively, Lawrence R. McGee, Sharon McKendry, David Sheppard, Stephen C. Young
  • Patent number: 7776867
    Abstract: The present invention relates to furanopyrimidine compounds having the general Formula I: and stereoisomers, tautomers, solvates, pharmaceutically acceptable salts and derivatives, and prodrugs thereof. The invention also includes pharmaceutical compositions comprising a compound of Formula I, methods of treating various diseases and conditions in a mammal, including inflammation, inhibition of T cell activation, proliferation, arthritis, organ transplant, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, Crohn's disease, lupus, hypersensitivity, type 1 diabetes, psoriasis, dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune diseases, glomerulonephritis, allergic diseases, asthma, hayfever, eczema, cancer, colon carcinoma and thymoma, comprising administering to the mammal a therapeutically effective amount of a compound of Formula I.
    Type: Grant
    Filed: June 29, 2005
    Date of Patent: August 17, 2010
    Assignee: Amgen Inc.
    Inventors: John Laird Buchanan, William H. Buckner, Simon A. Burkitt, Erin F. DiMauro, Christopher N. Farthing, Alexander D. Frenkel, Martin J. Harrison, Frank Kayser, Jinqian Liu, Sarah E. Lively, Teresa L. Marshall, David C. McGowan, Rajiv Sharma, Stephen J. Shuttleworth, Xiaotian Zhu
  • Patent number: 7635695
    Abstract: Compounds, compositions and methods that are useful in the treatment of inflammatory, immunoregulatory, metabolic, infectious and cell proliferative diseases or conditions are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, metabolism, infection and cell proliferation. The subject compounds contain a fused heterobicyclic ring.
    Type: Grant
    Filed: February 21, 2007
    Date of Patent: December 22, 2009
    Assignee: Amgen Inc.
    Inventors: Simon A. Burkitt, Mario G. Cardozo, Timothy D. Cushing, Michael R. DeGraffenreid, Christopher N. Farthing, Xiaolin Hao, Juan C. Jaen, Xian Yun Jiao, David J. Kopecky, Marc Labelle, Sarah E. Lively, Dustin L. McMinn, Sven P. Rasmussen, Youngsook Shin, Marie-Louise Smith, Andrew Smith
  • Publication number: 20090221584
    Abstract: Compounds, compositions and methods are provided that are useful in the treatment or prevention of a condition or disorder mediated by PPAR? or PPAR?. In particular, the compounds of the invention modulate the function of PPAR? or PPAR?. The subject methods are particularly useful in the treatment and/or prevention of diabetes, obesity, hypercholesterolemia, rheumatoid arthritis and atherosclerosis.
    Type: Application
    Filed: November 12, 2008
    Publication date: September 3, 2009
    Inventors: Philippe Bergeron, Christopher N. Farthing, Stuart D. Jones, John W. Liebeschuetz, Sarah E. Lively, Lawrence R. McGee, Sharon McKendry, David Sheppard, Stephen C. Young
  • Patent number: 7544702
    Abstract: Bisaryl-sulfonamide compounds having the formula wherein Ar, R1, R2, L, B, W, X, Y, and Z, compositions and methods are provided that are useful in the treatment or prevention of a condition or disorder mediated by PPAR? or PPAR?. In particular, the compounds of the invention modulate the function of PPAR? or PPAR?. The subject methods are particularly useful in the treatment and/or prevention of diabetes, obesity, hypercholesterolemia, rheumatoid arthritis and atherosclerosis.
    Type: Grant
    Filed: August 11, 2005
    Date of Patent: June 9, 2009
    Assignee: Amgen Inc.
    Inventors: Philippe Bergeron, Christopher N. Farthing, Stuart D. Jones, John W. Liebeschuetz, Sarah E. Lively, Lawrence R. McGee, Sharon McKendry, David Sheppard, Stephen C. Young
  • Patent number: 7358250
    Abstract: Compounds that modulate the action of ACK1 and LCK, and related compositions methods for treating ACK1- and LCK-mediated diseases are described. In one aspect, the compounds have the general structure: where the values of the substituents are provided herein.
    Type: Grant
    Filed: June 29, 2005
    Date of Patent: April 15, 2008
    Assignee: Amgen Inc.
    Inventors: Christopher N. Farthing, Paul Faulder, Alexander D. Frenkel, Martin J. Harrison, Xianyun Jiao, Frank Kayser, David J. Kopecky, Jinqian Liu, Sarah E. Lively, Rajiv Sharma, Stephen J. Shuttleworth
  • Patent number: 7199119
    Abstract: Compounds, compositions and methods that are useful in the treatment of inflammatory, immunoregulatory, metabolic, infectious and cell proliferative diseases or conditions are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, metabolism, infection and cell proliferation. The subject compounds contain a fused heterobicyclic ring.
    Type: Grant
    Filed: September 19, 2003
    Date of Patent: April 3, 2007
    Assignee: Amgen Inc.
    Inventors: Simon A. Burkitt, Mario G. Cardozo, Timothy D. Cushing, Michael R. DeGraffenreid, Christopher N. Farthing, Xiaolin Hao, Juan C. Jaen, XianYun Jiao, David J. Kopecky, Marc Labelle, Sarah E. Lively, Dustin L. McMinn, Sven P. Rasmussen, Youngsook Shin, Marie-Louise Smith, Andrew Smith
  • Publication number: 20040097485
    Abstract: Compounds, compositions and methods that are useful in the treatment of inflammatory, immunoregulatory, metabolic, infectious and cell proliferative diseases or conditions are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, metabolism, infection and cell proliferation. The subject compounds contain a fused heterobicyclic ring.
    Type: Application
    Filed: September 19, 2003
    Publication date: May 20, 2004
    Applicant: Tularik Inc.
    Inventors: Simon A. Burkitt, Mario G. Cardozo, Timothy D. Cushing, Michael R. DeGraffenreid, Christopher N. Farthing, Xiaolin Hao, Juan C. Jaen, Xian Yun Jiao, David J. Kopecky, Marc Labelle, Sarah E. Lively, Dustin L. McMinn, Sven P. Rasmussen, Youngsook Shin, Andrew Smith, Marie-Louise Smith